These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 8105892)
1. Inhibition of the multidrug resistance efflux pump. Wigler PW; Patterson FK Biochim Biophys Acta; 1993 Oct; 1154(2):173-81. PubMed ID: 8105892 [TBL] [Abstract][Full Text] [Related]
2. Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Wigler PW; Patterson FK Biochim Biophys Acta; 1994 Jan; 1189(1):1-6. PubMed ID: 7905747 [TBL] [Abstract][Full Text] [Related]
3. Mathematical models for multidrug resistance and its reversal. Michelson S Cytotechnology; 1993; 12(1-3):315-24. PubMed ID: 7765330 [TBL] [Abstract][Full Text] [Related]
4. Cellular drug efflux and reversal therapy of cancer. Wigler PW J Bioenerg Biomembr; 1996 Jun; 28(3):279-84. PubMed ID: 8807402 [TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance in cancer cells. Wigler PW J Natl Cancer Inst; 1994 Jan; 86(2):148-50. PubMed ID: 7903703 [No Abstract] [Full Text] [Related]
6. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Spoelstra EC; Westerhoff HV; Dekker H; Lankelma J Eur J Biochem; 1992 Jul; 207(2):567-79. PubMed ID: 1353020 [TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the multidrug transporter. Germann UA Cytotechnology; 1993; 12(1-3):33-62. PubMed ID: 7765331 [TBL] [Abstract][Full Text] [Related]
8. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Pereira E; Borrel MN; Fiallo M; Garnier-Suillerot A Biochim Biophys Acta; 1994 Jan; 1225(2):209-16. PubMed ID: 7904185 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Nielsen D; Skovsgaard T Biochim Biophys Acta; 1992 Jul; 1139(3):169-83. PubMed ID: 1352705 [TBL] [Abstract][Full Text] [Related]
10. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Marbeuf-Gueye C; Ettori D; Priebe W; Kozlowski H; Garnier-Suillerot A Biochim Biophys Acta; 1999 Jul; 1450(3):374-84. PubMed ID: 10395948 [TBL] [Abstract][Full Text] [Related]
11. A mathematical model of the P-glycoprotein pump as a mediator of multidrug resistance. Michelson S; Slate D Bull Math Biol; 1992 Nov; 54(6):1023-38. PubMed ID: 1355383 [TBL] [Abstract][Full Text] [Related]
12. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. Borrel MN; Pereira E; Fiallo M; Garnier-Suillerot A Eur J Biochem; 1994 Jul; 223(1):125-33. PubMed ID: 7518390 [TBL] [Abstract][Full Text] [Related]
14. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099 [TBL] [Abstract][Full Text] [Related]
15. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Arceci RJ; Stieglitz K; Bierer BE Blood; 1992 Sep; 80(6):1528-36. PubMed ID: 1381629 [TBL] [Abstract][Full Text] [Related]
17. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Muñoz-Martínez F; Lu P; Cortés-Selva F; Pérez-Victoria JM; Jiménez IA; Ravelo AG; Sharom FJ; Gamarro F; Castanys S Cancer Res; 2004 Oct; 64(19):7130-8. PubMed ID: 15466210 [TBL] [Abstract][Full Text] [Related]